Laura Alder, Thoracic Medical Oncologist at Duke University School of Medicine, shared on LinkedIn:
“Honored to present our Tarlatamab data in active brain mets and treatment beyond isolated CNS progression at SNO/ASCO 2026!
Key findings:
- Intracranial activity in a trial-excluded population: 33% intracranial response in patients with ACTIVE, radiation-naïve brain metastases, supporting genuine CNS activity of the drug itself (overall intracranial ORR 38.9% across 36 evaluable patients).
- Reassuring safety with CNS radiation: no clear increase in severe CRS or ICANS when CNS-directed radiation was given before or concurrently with tarlatamab.
- Treatment beyond isolated CNS progression is feasible: patients who continued tarlatamab with local therapy (SRS/WBRT) gained a median of 4.3 additional months on therapy after CNS progression.
To our knowledge, this is the first report of continuing a BiTE therapy beyond CNS progression in SCLC. These are hypothesis-generating, real-world data from a retrospective analysis with small subgroups: prospective validation is needed.
A sincere thank you to the chairs and organizers of SNO/ASCO 2026 for the opportunity to share this work, and to my outstanding co-authors and collaborators across both institutions, Dr Jona Hattangadi-Gluth, Dr Jarushka Naidoo, Dr Michelle Kim, Dr Kevin Chen, Dr Alexis Green, Dr Daniel Hess and Dr Shetal Patel.”
Other articles featuring Laura Alder on OncoDaily.
